Evaxion Biotech Receives Positive Feedback on Patent Application for Personalized Vaccine Targets

Evaxion Biotech A/S, a clinical-stage TechBio company known for its AI-Immunology™ powered vaccines, has received favorable feedback regarding its recent patent application for a novel type of personalized vaccine target.

The patent application, designated PCT/EP2022/086444, details a method for identifying a new category of tumor vaccine targets derived from Endogenous Retroviruses (ERVs) using Evaxion’s proprietary AI-Immunology™ platform.

This allows Evaxion to discover cancer-specific targets, broadening the potential application of its personalized vaccines to a wider range of cancer patients.

See also: Valo Therapeutics Aims to Improve Personalized Immunotherapy With a New Tech

Christian Kanstrup, CEO of Evaxion, expressed his enthusiasm:

“The positive feedback in the patentability report, confirming the novelty and inventive step of all relevant claims in our personalized ERV-based vaccine, is a significant endorsement from the World Intellectual Property Organization. This recognition underscores our commitment to advancing cancer treatment through innovation and solidifies our leadership in the field of personalized cancer vaccines. Building a robust intellectual property portfolio is vital to our multi-partner strategy. We remain dedicated to advancing our AI-Immunology™ platform and delivering cutting-edge solutions to patients with high unmet medical needs.”

ERVs, or Endogenous Retroviruses, are ancient viral remnants embedded in the human genome. Typically dormant, ERVs become overexpressed in cancer cells but not in healthy tissue, making them prime targets for cancer vaccines.

Topics:
Novel Therapeutics